Context: Major histocompatibility complex class I allele HLA-A*26:01 and human leukocyte antigen (HLA) supertype A01 (STA01) are increased in idiopathic hypoparathyroidism (IH). However, cellmediated autoimmune responses directed against the calcium-sensing receptor (CaSR) have not been demonstrated.
calcium-sensing receptor (CaSR) and NACHT leucine-rich repeat protein 5, respectively, in polyendocrinopathycandidiasis-ectodermal dystrophy-associated hypoparathyroidism. Rarity of the disease and lack of availability of a large homogeneous cohort of patients at a given center pose a major limitation for detailed investigation of the etiopathogenetic mechanisms of IH. For instance, only 47 patients of IH were observed by Underbjerg et al. (7) while screening the National Registry in Denmark during 1977 to 2012 (8) .
We have been following a large number of IH patients in our cohort since 1998 to investigate the unique clinical features and etiopathogenesis of IH (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Briefly, 10.9% of them had the glial cell missing 2 (GCM2) gene mutation, 0.7% had the PTH gene mutation, and none of them had the CaSR mutation (10, 11, 14) . Autoantibodies against CaSR, interferon (IFN)-a, and NACHT leucinerich repeat protein 5 were present in 12.5%, 3.5%, and 0.69% of cases, respectively (16, 17, 21) . Recently, we have shown a strong association of the major histocompatibility complex (MHC) class I allele HLA-A*26:01 in patients with IH, which has functional relevance. Of the IH patients, 50.75% had HLA-A*26:01 compared with 9.98% of the healthy controls (18) . The function of MHC molecules is to present antigenic peptides to the T lymphocytes. Whereas MHC class II molecules present the antigenic peptides to CD4 + helper T cells, MHC class I molecules present the peptides to CD8 + cytotoxic T cells, the effectors involved in destruction of specific cells that may be either infected or targeted for autoimmune destruction. MHC molecules are extremely polymorphic, and peptides presented by them have allele-specific motifs; however, similar peptides may be presented by several allelic forms that can be clustered into supertypes (22) . An analysis of the supertypes revealed that MHC class I human leukocyte antigen (HLA)-A supertype A01 was significantly increased in IH (P , 9.18 3 10 9 ; odds ratio = 2.95). Because MHC class I molecules present antigenic peptides to CD8 + cytotoxic T cells for their effector functions, such a strong association with the MHC class I allele and its supertype A01 implicate cytotoxic CD8 + T cells to induce parathyroid autoimmunity (18) . Thus, it was expected that these molecules may be involved in presenting autoantigenic peptides to CD8 + cytotoxic T cells. IFN-g secretion is a hallmark of cytotoxic T cells, so we used a very sensitive technique that is ex vivo IFN-g ELISPOT assay to elucidate antigen specific T-cell responses in IH patients and compared them with those of healthy controls. We demonstrate the presence of autoreactive memory CD8 + T cells specific for the peptides derived from CaSR antigens in IH patients. Our results further show that a few selected peptides induced a significant increase in IFN-g stimulation indices (SIs) in the HLA-A superytpe A01 restricted manner.
Materials and Methods
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of 45 patients with IH being followed up with in the endocrine clinic of the All India Institute of Medical Sciences in New Delhi, India, and 22 healthy volunteers after obtaining informed consents and clearance from the Human Ethics Committee of All India Institute of Medical Sciences in accordance with the Declaration of Helsinki. Most of the patients, included in the present report, have been part of our earlier studies (15, (17) (18) (19) . The diagnosis of hypoparathyroidism was based on clinical and biochemical features of hypocalcaemia, hyperphosphatemia, normal blood urea, serum creatinine, and low serum parathyroid hormone (PTH) levels. Patients with postsurgical hypoparathyroidism were excluded. None of patients in the current study had clinical features of polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome, and serum cortisol and adrenocorticotropic hormone were normal in all. The IFN-a autoantibody was positive in 1 of the 44 patients tested. The clinical features of the 45 patients in the current study-including male to female ratio (22:23) , age at onset of symptoms (mean 6 SD = 25.2 6 13.48 years), age at diagnosis of the disease (31.3 6 12.62 years), body mass index (20.8 6 3.82 kg/m 2 ), total duration of illness (14.1 6 7.23 years), cataract (48.8%), and intracranial calcification (75.0%)-conformed to those described earlier in our larger cohort (21) . Their serum total calcium, inorganic phosphate, and intact parathyroid hormone at diagnosis were 5.4 6 1.01 mg/dL, 7.1 6 1.44 mg/dL, and 7.6 6 8.07 pg/mL, respectively. Seven of the 45 patients had coexistent hypothyroidism and were on thyroxine replacement. CaSR antibody positivity, at 2.5 standard deviation score of control, was present in 8 (23.5%) (16) . None of the patients had mutation of the CaSR or PTH genes. R110W mutation of the GCM2 gene was seen in 4 of the 44 patients tested (9.1%). All these patients were advised a daily dose of 1 to 2 gm of elemental calcium and 0.5 to 3.0 mg of 1-a (OH)D and underwent regular follow-up at variable intervals for monitoring of serum total calcium, inorganic phosphorus, urinary calcium excretion, and abdomen ultrasound. The therapy was adjusted to maintain their serum calcium in the range of 8.0 to 8.5 mg/dL. Study controls were 22 healthy volunteers from among students and staff at our institutes who consented to participate in the study [male to female ratio = 15:7, mean (6 SD) age = 29. 
Peptide synthesis and peptide screening for ELISPOT assay
To study the immune response against autoantigenic peptides of CaSR that would fit the peptide-binding groove of MHC class I allele, HLA-A*26:01, 2 peptide-predicting software programs, SYFPEITHI (http://www.ebi.ac.uk/cgi-bin/imgt/HLA/align.cgi) and T-epitope designer (http://www.bioinformation.net/ted/), were used using the full-length protein sequences of CaSR (Fig. 1) . A total of 24 peptides with maximum binding scores in the 2 software programs were commercially synthesized (Think Peptides, Proimmune, Oxford, United Kingdom). All these peptides were predicted to bind to HLA-A*26:01 molecule with high affinity. Their sequences and binding scores are shown in Table 1 . The extracellular domain of human CaSR was expressed in Escherichia coli and purified using Ni-NTA agarose column (Qiagen, Hilden, Germany) and characterized using anti-CaSR monoclonal (CaSRMab, Santa Cruz Biotechnology), liquid chromatography, and tandem mass spectrometry (QSTAR, XL system; Applied Biosystems, Foster City, CA) as described earlier (17) .
IFN-g ELISPOT assay
All 24 peptides were screened for their IFN-g responses using 10 mM and 20 mM final concentrations, and recombinant CaSR (rCaSR) was screened at concentrations of 10 mg, 20 mg, and 30 mg /mL in the initial 9 patient samples to determine the optimum dose required to induce an immune response. ELISPOT assays were carried out as per the manufacturer's instructions with some modifications. Briefly, 96-well PVDF plates (Millipore, Bedford, MA) were coated with 100 mL per well of human IFN-g-specific capture monoclonal antibody (15 mg/mL) overnight at 4°C. Unbound antibody was removed by washing 5 times with phosphatebuffered saline (PBS). 100,000 PBMCs/well in duplicate were cultured in the capture antibody-coated PVDF plates in the presence of medium alone as unstimulated negative control, 10 mM or 20 mM of synthetic CaSR peptides or rCasR, or a mix of phorbol myristate acetate (25 ng/mL) plus ionomycin (500 ng/mL) as positive control in RPMI 1640 medium with 10% fetal bovine serum for 48 hours in humidified, 5% CO 2 atmosphere at 37°C. After 48 hours, the plates were washed 5 times with PBS to remove the cells. Further, 100 ml of biotinylated human IFN-g antibody (1 mg/mL in PBS) was added (to detect bound IFN-g) and incubated overnight at 4°C, unbound antibodies were removed by washing 5 times with PBS, and 50 ml of (1:1000 diluted) streptavidin-ALP (Mabtech, Nacka Strand, Sweden) was added for 1 hour at room temperature; the plate was washed 4 times with PBS and 1 time with TNM buffer (10 mM Tris pH 8.5, 100 mM NaCl, 50 mM MgCl 2 ). Subsequently, the reaction was developed with 5-bromo-4-chloro-3-indolyl-phosphate-nitro blue tetrazolium (Promega, Madison, WI) in TNM buffer. After 15 minutes, the color reaction was stopped by rinsing with water. IFN-g spots were counted in all the wells of the PVDF plates using computer-assisted ImmunoSpot image analyzer as shown in Supplemental Fig. 1 (Cellular Technology Limited, Shaker Heights, OH), and a peptide-specific response was considered positive when the IFN-g SI $2. The IFN-g SI was calculated by dividing the number of spots in the peptide well by the number of spots in unstimulated negative control (23) . Concentrations of peptides giving the best SIs were used for the ELISPOT assays for the remaining 36 patients and 22 control samples following the same protocol.
HLA typing
DNA extraction was carried out by standard procedures from fresh whole blood samples collected in anticoagulant EDTA. Alleles of HLA-A, HLA-B, and HLA-DRB1 were determined using polymerase chain reaction followed by hybridization with sequence-specific oligonucleotide probes as described earlier (24) using a bead-based technology (Luminex, Austin, TX) following manufacturer's instructions (Labtype SSO kit from One Lambda, Canoga Park, CA). The latest nomenclature for the HLA system was used to designate the alleles of the 3 loci studied (25) .
Statistical analysis
For analysis of peptide specific IFN-g SIs, unpaired t tests with Welch's correction was used using GraphPad Prism 4 software (San Diego, CA). A x 2 test was used to compare the significance of number of individuals giving peptide specific press.endocrine.org/journal/jcempositive IFN-g response in patients and controls, using Stata 9.2 statistical program. Fisher's exact test was used whenever the numbers were less than 5 in any group. In such cases, odds ratios and 95% confidence intervals were calculated using Woolf's (26) method with Haldane's (27) modification as described earlier (28) . A value of P , 0.05 was considered significant.
Results
Twenty-four synthetic peptides (RH1 to RH24) and rCaSR were screened in PBMCs of 9 initial patients with IH to determine the optimal dose required to induce IFN-g ELISPOTS. The screening results revealed that some peptides could induce an IFN-g response at 10 mM concentration (RH1, RH5, RH6, RH9, RH12, RH15, RH18, RH20, RH21, and RH22), whereas some others induced the same at 20 mM concentration (RH3, RH4, RH7, RH8, RH10, RH11, RH13, RH14, RH16, RH17, and RH19; Supplemental Fig. 2) . Three of the peptides tested gave only a few spots during the initial screening, so they were not used for further ELISPOT assays. The rCaSR protein gave best results at 30 mg/mL concentration, so further ELISPOT assays with more number of samples were done using this concentration. Thirty-seven of the 45 patients (82.2%) showed IFN-g ELISPOTs with SI $ 2, with 1 or more peptides tested (i.e., they responded to these peptides in ex vivo IFN-g ELISPOT assay; Supplemental Fig. 3 ). Although 17 of the 22 healthy controls also responded to 1 or the other peptide of CaSR, the magnitude of the response was much less as compared with the patients with an average SI , 2 for all the peptides tested (Supplemental Figs. 3-6 ). First, we compared the number of patients and controls responding to the individual peptides (with SI $ 2) and observed that significantly higher number of patients responded to peptides RH1, RH4, RH11, and RH22 (Table 2 ) when compared with healthy controls. Further, we compared the magnitude of IFN-g responses in IH cases and controls. Significantly higher IFN-g responses were observed with peptides RH7, RH8, RH14, RH15, RH20 and RH21 in IH cases compared with healthy controls (Supplemental Figs. 3-6 ).
We further divided the patients and controls into HLA-A supertype A01 positive (ST01+) and HLA-A supertype A01 negative (ST01-) groups to study whether these responses were MHC restricted. The rationale for this combination was that HLA-A*26:01 falls in supertype A01, which was significantly increased in patients and similar peptides may be presented by several allelic forms clustered in this supertype. Thirty patients turned out to be positive for the supertype A01, and 15 patients were negative for this supertype. Among the healthy controls, 13 individuals were supertype A01-positive and 9 were negative. Peptides RH1 to RH6 did not show any significant differences in ST01+ or ST01-IH patients and controls (Supplemental Fig. 7) . Peptide RH7 showed significantly higher response in ST01+ patients compared with ST01-patients, ST01+ healthy controls and also ST01-healthy (Figs. 3, 4) . Peptide RH15 elicited a significantly higher response in ST01+ IH patients compared with ST01-controls. Interestingly, peptide RH16 did not show any significant differences (Supplemental Fig. 5 ) when patient and controls groups were compared as a whole (P , 0.06). However, it elicited ST01 restricted IFN-g response when IH patients and controls were divided into ST01+ and ST01-groups, that is, significantly higher IFN-g SIs were induced by peptide RH16 in ST01+ IH patients compared with ST01-patients. This peptide also induced significantly higher response in ST01+ IH patients compared with ST01-controls (Figs. 3, 4) . Peptide RH20 elicited significantly higher response in ST01+ patients compared with ST01+ and ST01-healthy controls (Fig. 4 , Supplemental Fig. 8 ). Peptide RH21 induced significantly higher IFN-g response in ST01+ patients compared with ST01-healthy controls (Fig. 4, Supplemental Fig. 9 ). IFN-g SIs shown here depict CD8 + memory T cells ex vivo specific for autoantigenic peptides derived from the CaSR.
Discussion
Investigation of etiopathogenesis of IH has been ongoing. Humoral autoimmune responses have been shown to be variable in different studies; that is, variable percentages of patients have been shown to have autoantibodies against CaSR, the autoantigen implicated in the manifestation of the disease. Because we had earlier reported a very strong association of MHC class I supertype A01 with IH (18), it was expected that these molecules may be involved in presenting autoantigenic peptides to CD8 + cytotoxic T cells. IFN-g secretion is a hallmark of cytotoxic T cells, so we used a very sensitive technique that is ELISPOT assay to elucidate antigen-specific T-cell responses in IH patients and compared them with those of healthy controls. Our ex vivo IFN-g ELISPOT assays clearly demonstrate the presence of autoantigen-specific memory CD8 + T cells in the peripheral circulation of patients with IH. ELISPOT assay measures the biologically active cytokine naturally released by individual cells over the entire duration of the assay. The technique is so sensitive that it can detect as low as 1/300,000 cells secreting a cytokine as compared with 1/5000 cells using flow cytometry (29) . In our study, we have stimulated PBMCs with the peptides of CaSR as well as recombinant protein for extracellular domain of CaSR for 48 hours ex vivo. Under these conditions, naïve T cells are not expected to produce IFN-g, as they need several days to differentiate into effector T cells in vitro (29) . Thus, the IFN-g-secreting cells that we observe on ex vivo stimulation reflect the frequency of memory T cells that were specific for these peptides in vivo and also their commitment to produce IFN-g, which was imprinted on them in vivo (29).
Our results show that 82.2% of IH patients, irrespective of their being positive or negative for supertype A01, showed positive response with 1 or the other peptide of CaSR. However, MHC-restricted (i.e., supertype A01-restricted) responses were observed with peptides RH7, RH9, and RH16 in IH patients. These results suggest these peptidespecific T cells had encountered the peptides in vivo and, when stimulated ex vivo, elicited a memory response. In the current study, we have investigated only 21 peptides of CaSR; however, several other peptides may be presented by MHC molecules during autoimmune responses that we have not tested. Hence, in the 17.8% of IH patients in which we did not observe any IFN-g response, memory T cells specific for other CaSR peptides may be present that were not tested in the current study. RH8, RH14, RH15, RH20, and RH21 peptides showed specific induction of IFN-g response in IH patients, irrespective of their being positive or negative for supertype A01. These data suggest that even in supertype A01-negative IH patients, memory CD8 + T cells specific for these peptides exist because these peptides may be promiscuous; that is, they may be restricted by other HLA alleles as well. Interestingly, some of the healthy controls also responded to the CaSR peptides, although the magnitude of their response was much less as compared with patients showing positive response, which was intriguing. There may be some underlying clinically occult preclinical autoimmune conditions or molecular mimicry responsible for cytotoxic T-cell responses in healthy controls (17) . The possibility of cross-reactive cytotoxic T cells against Saccharomonospora viridis or Clostridium sporogenes-which are found in vegetables, hay, soil and human intestinal flora or other microorganisms-cannot be ruled out and needs to be studied further. Our data suggest that peptides corresponding to CaSR amino acid positions 353 to 382 (extra cellular domain, the Venus flytrap), 510 to 533 (end of the Venus flytrap domain), 806 to 815, and 836 to 845 (7-transmembrane domain) (3) are the most immunogenic, as they showed significantly higher recall responses in IH patients. While humoral autoimmune responses against CaSR have been reported in earlier studies, this is the first study demonstrating the presence of cell-mediated immunity in the form of IFN-g-secreting T cells specific for the immunogenic peptides of CaSR in the IH patients. However, the mechanism by which the CD8 + cytotoxic T cells damage the parathyroid cells, that is, by perforin-granzyme or FasFas ligand interaction, is not clear. The ELISPOT assay, in spite of being a very sensitive assay, cannot clearly decipher the phenotype of the IFN-g-secreting T cells (i.e., whether they are CD4 + or CD8 + ); however, one can speculate with reasonable confidence that these are CD8 + T cells, as they show MHC class I restriction to 9-mer peptides that would be presented by MHC class I molecules only. Although flow cytometric analysis can clearly demonstrate whether the IFN-g-secreting T cells are CD4 + or CD8 + , it may not be able to capture small number of effector cells specific for the autoantigens as it can detect only 1 in 5000 cells press.endocrine.org/journal/jcemcompared with 1/300,000 cells secreting a cytokine by ELISPOT assay (29 
